Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

University of British Columbia

$27,000.00

Mechanisms of Resistance to KRAS Inhibitors in Pancreatic Cancer Under Hypoxic Stress

EF 2025-26

Résumé
Pancreatic cancer is one of the deadliest forms of cancer, with very few effective treatments. Most pancreatic tumours contain a genetic change in the gene KRAS, leading to constant KRAS activation, causing continuous growth of the cancer cells. Drugs that directly block mutant KRAS have shown early success, but recent data have shown the tumours quickly find ways to gain resistance to those drugs, causing disease progression. One potential explanation for this phenomenon may be due to the microenvironment inside the pancreatic tumours. These tumours are dense, poorly supplied with blood, and often have very low oxygen, which force cancer cells to change how they make and use energy. These changes may help them survive even when KRAS is inhibited. My research will study how pancreatic cancer cells become resistant to KRAS-inhibitors due to the low-oxygen conditions of the tumour. First, I will utilize pancreatic cancer cells with different KRAS mutations and expose them to KRAS inhibitors until resistant cells emerge. I will then examine how resistant cancer cells grow and how much cell death occurs when they are exposed to KRAS inhibitors. Next, I will study how gene activity, protein levels, and metabolism differ between parent cells and resistant cells, both with and without oxygen to identify pathways that enable pancreatic cancer cells to survive KRAS inhibition. Finally, I will test these findings in patient-derived tumour organoids and mouse models that reflect some of the conditions cancer cells experience inside the body. This research will provide insight into how pancreatic cancer cells adapt to survive KRAS inhibition, which will propose methods to reduce resistance and identify new treatment options for patients.
Programme
Master's Award: Canada Graduate Research Scholarships - Master's program
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
573308
Name
Zanewich Brinnley E
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Mechanisms of Resistance to KRAS Inhibitors in Pancreatic Cancer Under Hypoxic Stress
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Adaptive Signalling; Cancer Therapy; Drug Resistance; Hypoxia; Kras Inhibitors; Kras Mutations; Metabolic Reprogramming; Pancreatic Ductal Adenocarcinoma (Pdac); Therapeutic Response; Tumour Microenvironment (Tme)
Abstract
Pancreatic cancer is one of the deadliest forms of cancer, with very few effective treatments. Most pancreatic tumours contain a genetic change in the gene KRAS, leading to constant KRAS activation, causing continuous growth of the cancer cells. Drugs that directly block mutant KRAS have shown early success, but recent data have shown the tumours quickly find ways to gain resistance to those drugs, causing disease progression. One potential explanation for this phenomenon may be due to the microenvironment inside the pancreatic tumours. These tumours are dense, poorly supplied with blood, and often have very low oxygen, which force cancer cells to change how they make and use energy. These changes may help them survive even when KRAS is inhibited. My research will study how pancreatic cancer cells become resistant to KRAS-inhibitors due to the low-oxygen conditions of the tumour. First, I will utilize pancreatic cancer cells with different KRAS mutations and expose them to KRAS inhibitors until resistant cells emerge. I will then examine how resistant cancer cells grow and how much cell death occurs when they are exposed to KRAS inhibitors. Next, I will study how gene activity, protein levels, and metabolism differ between parent cells and resistant cells, both with and without oxygen to identify pathways that enable pancreatic cancer cells to survive KRAS inhibition. Finally, I will test these findings in patient-derived tumour organoids and mouse models that reflect some of the conditions cancer cells experience inside the body. This research will provide insight into how pancreatic cancer cells adapt to survive KRAS inhibition, which will propose methods to reduce resistance and identify new treatment options for patients.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Zanewich, Brinnley E
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~